Agreement between circulating IGF-I, IGFBP-1 and IGFBP-3 levels measured by current assays versus unavailable assays previously used in epidemiological studies

Chino S. Aneke-Nash, Clara Dominguez-Islas, Petra Bůžková, Qibin Qi, Xiaonan (Nan) Xue, Michael Pollak, Howard Strickler, Robert C. Kaplan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Levels of insulin-like growth factor (IGF) proteins are associated with the risk of cancer and mortality. IGF assays produced by Diagnostic Systems Laboratories (DSL) were widely used in epidemiological studies, were not calibrated against recommended standards and are no longer commercially available. Design: In a split sample study among 1471 adults participating in the Cardiovascular Health Study, we compared values obtained using DSL assays with alternative assays for serum IGF-I (Immunodiagnostic Systems, IDS), IGFBP-1 (American Laboratory Products Company, ALPCO) and IGFBP-3 (IDS). Results: Results were compared using kernel density estimation plots, quartile analysis with weighted kappa statistics and linear regression models to assess the concordance of data from the different assays. Participants had a mean age of 77 years. Results between alternative assays were strongly correlated (IGF-I, r = 0.93 for DSL versus IDS; log-IGFBP-1, r = 0.90 for DSL versus ALPCO; IGFBP-3, r = 0.92 for DSL versus IDS). Cross tabulations showed that participants were usually in the same quartile categories regardless of the assay used (overall agreement, 74% for IGF-I, 64% for IGFBP-1, 71% for IGFBP-3). Weighted kappa also showed substantial agreement between assays (kw, 0.78 for IGF-I, 0.69 for IGFBP-1, 0.76 for IGFBP-3). Regressions of levels obtained with DSL assays (denoted X) to alternative assays were, IGF-I: 0.52X + 15.2 ng/ml, log-IGFBP-1: 1.01X - 1.73 ng/ml IGFBP-3: 0.87X + 791.1 ng/ml. Serum values of IGF-I, IGFBP-1 and IGFBP-3 measured using alternative assays are moderately correlated. Conclusions: Care is needed in the interpretation of data sets involving IGF analytes if assay methodologies are not uniform.

Original languageEnglish (US)
Pages (from-to)11-16
Number of pages6
JournalGrowth Hormone and IGF Research
Volume26
DOIs
StatePublished - Feb 1 2016

Fingerprint

Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I
Epidemiologic Studies
Somatomedins
Linear Models
Spatial Analysis
Serum
Mortality
Health

Keywords

  • Diabetes
  • Glycemic status
  • Insulin-like growth factor

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{6d9c67367dea4a1795963099cd6aca4d,
title = "Agreement between circulating IGF-I, IGFBP-1 and IGFBP-3 levels measured by current assays versus unavailable assays previously used in epidemiological studies",
abstract = "Objective: Levels of insulin-like growth factor (IGF) proteins are associated with the risk of cancer and mortality. IGF assays produced by Diagnostic Systems Laboratories (DSL) were widely used in epidemiological studies, were not calibrated against recommended standards and are no longer commercially available. Design: In a split sample study among 1471 adults participating in the Cardiovascular Health Study, we compared values obtained using DSL assays with alternative assays for serum IGF-I (Immunodiagnostic Systems, IDS), IGFBP-1 (American Laboratory Products Company, ALPCO) and IGFBP-3 (IDS). Results: Results were compared using kernel density estimation plots, quartile analysis with weighted kappa statistics and linear regression models to assess the concordance of data from the different assays. Participants had a mean age of 77 years. Results between alternative assays were strongly correlated (IGF-I, r = 0.93 for DSL versus IDS; log-IGFBP-1, r = 0.90 for DSL versus ALPCO; IGFBP-3, r = 0.92 for DSL versus IDS). Cross tabulations showed that participants were usually in the same quartile categories regardless of the assay used (overall agreement, 74{\%} for IGF-I, 64{\%} for IGFBP-1, 71{\%} for IGFBP-3). Weighted kappa also showed substantial agreement between assays (kw, 0.78 for IGF-I, 0.69 for IGFBP-1, 0.76 for IGFBP-3). Regressions of levels obtained with DSL assays (denoted X) to alternative assays were, IGF-I: 0.52X + 15.2 ng/ml, log-IGFBP-1: 1.01X - 1.73 ng/ml IGFBP-3: 0.87X + 791.1 ng/ml. Serum values of IGF-I, IGFBP-1 and IGFBP-3 measured using alternative assays are moderately correlated. Conclusions: Care is needed in the interpretation of data sets involving IGF analytes if assay methodologies are not uniform.",
keywords = "Diabetes, Glycemic status, Insulin-like growth factor",
author = "Aneke-Nash, {Chino S.} and Clara Dominguez-Islas and Petra Bůžkov{\'a} and Qibin Qi and Xue, {Xiaonan (Nan)} and Michael Pollak and Howard Strickler and Kaplan, {Robert C.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.ghir.2015.12.007",
language = "English (US)",
volume = "26",
pages = "11--16",
journal = "Endocrinology and Metabolism",
issn = "1096-6374",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Agreement between circulating IGF-I, IGFBP-1 and IGFBP-3 levels measured by current assays versus unavailable assays previously used in epidemiological studies

AU - Aneke-Nash, Chino S.

AU - Dominguez-Islas, Clara

AU - Bůžková, Petra

AU - Qi, Qibin

AU - Xue, Xiaonan (Nan)

AU - Pollak, Michael

AU - Strickler, Howard

AU - Kaplan, Robert C.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Objective: Levels of insulin-like growth factor (IGF) proteins are associated with the risk of cancer and mortality. IGF assays produced by Diagnostic Systems Laboratories (DSL) were widely used in epidemiological studies, were not calibrated against recommended standards and are no longer commercially available. Design: In a split sample study among 1471 adults participating in the Cardiovascular Health Study, we compared values obtained using DSL assays with alternative assays for serum IGF-I (Immunodiagnostic Systems, IDS), IGFBP-1 (American Laboratory Products Company, ALPCO) and IGFBP-3 (IDS). Results: Results were compared using kernel density estimation plots, quartile analysis with weighted kappa statistics and linear regression models to assess the concordance of data from the different assays. Participants had a mean age of 77 years. Results between alternative assays were strongly correlated (IGF-I, r = 0.93 for DSL versus IDS; log-IGFBP-1, r = 0.90 for DSL versus ALPCO; IGFBP-3, r = 0.92 for DSL versus IDS). Cross tabulations showed that participants were usually in the same quartile categories regardless of the assay used (overall agreement, 74% for IGF-I, 64% for IGFBP-1, 71% for IGFBP-3). Weighted kappa also showed substantial agreement between assays (kw, 0.78 for IGF-I, 0.69 for IGFBP-1, 0.76 for IGFBP-3). Regressions of levels obtained with DSL assays (denoted X) to alternative assays were, IGF-I: 0.52X + 15.2 ng/ml, log-IGFBP-1: 1.01X - 1.73 ng/ml IGFBP-3: 0.87X + 791.1 ng/ml. Serum values of IGF-I, IGFBP-1 and IGFBP-3 measured using alternative assays are moderately correlated. Conclusions: Care is needed in the interpretation of data sets involving IGF analytes if assay methodologies are not uniform.

AB - Objective: Levels of insulin-like growth factor (IGF) proteins are associated with the risk of cancer and mortality. IGF assays produced by Diagnostic Systems Laboratories (DSL) were widely used in epidemiological studies, were not calibrated against recommended standards and are no longer commercially available. Design: In a split sample study among 1471 adults participating in the Cardiovascular Health Study, we compared values obtained using DSL assays with alternative assays for serum IGF-I (Immunodiagnostic Systems, IDS), IGFBP-1 (American Laboratory Products Company, ALPCO) and IGFBP-3 (IDS). Results: Results were compared using kernel density estimation plots, quartile analysis with weighted kappa statistics and linear regression models to assess the concordance of data from the different assays. Participants had a mean age of 77 years. Results between alternative assays were strongly correlated (IGF-I, r = 0.93 for DSL versus IDS; log-IGFBP-1, r = 0.90 for DSL versus ALPCO; IGFBP-3, r = 0.92 for DSL versus IDS). Cross tabulations showed that participants were usually in the same quartile categories regardless of the assay used (overall agreement, 74% for IGF-I, 64% for IGFBP-1, 71% for IGFBP-3). Weighted kappa also showed substantial agreement between assays (kw, 0.78 for IGF-I, 0.69 for IGFBP-1, 0.76 for IGFBP-3). Regressions of levels obtained with DSL assays (denoted X) to alternative assays were, IGF-I: 0.52X + 15.2 ng/ml, log-IGFBP-1: 1.01X - 1.73 ng/ml IGFBP-3: 0.87X + 791.1 ng/ml. Serum values of IGF-I, IGFBP-1 and IGFBP-3 measured using alternative assays are moderately correlated. Conclusions: Care is needed in the interpretation of data sets involving IGF analytes if assay methodologies are not uniform.

KW - Diabetes

KW - Glycemic status

KW - Insulin-like growth factor

UR - http://www.scopus.com/inward/record.url?scp=84958743286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958743286&partnerID=8YFLogxK

U2 - 10.1016/j.ghir.2015.12.007

DO - 10.1016/j.ghir.2015.12.007

M3 - Article

C2 - 26774400

AN - SCOPUS:84958743286

VL - 26

SP - 11

EP - 16

JO - Endocrinology and Metabolism

JF - Endocrinology and Metabolism

SN - 1096-6374

ER -